Chronic thromboembolic pulmonary hypertension in UAE: the first reported seven year outcomes from a tertiary center in UAE

Khaled Saleh, Jihad Mallat, Kelly Dougherty, Mohannad Ghanem, Ahmed Ghorab, Reem Al‐Saadi, Manyoo Agrawal, Simi Salim, Sara Abdalla, Naureen Khan, Hani SabbourmedRxiv 2023 · DOI

Chronic Thromboembolic Pulmonary Hypertension (CTEPH) is a debilitating and potentially fatal condition caused by unresolved blood clots in the pulmonary arteries. While extensive registries exist for North American and European populations, there has been a significant "data desert" regarding CTEPH in the Middle East and North Africa (MENA) region. This study presents the first long-term registry of CTEPH in the United Arab Emirates (UAE), tracking patients over a seven-year period at a tertiary referral center in Abu Dhabi.

The Clinical Landscape of CTEPH

CTEPH is unique among forms of pulmonary hypertension because it is potentially curable through a complex surgical procedure known as pulmonary thromboendarterectomy (PTE). However, the clinical characteristics, age of onset, and response to therapy can vary significantly by region. Understanding these local nuances is critical for optimizing patient care and resource allocation.

Methodology

Researchers at Cleveland Clinic Abu Dhabi conducted a retrospective study of 39 consecutive adult patients diagnosed with CTEPH between January 2015 and April 2022. Diagnosis followed standardized protocols, including right heart catheterization (RHC), ventilation-perfusion (V/Q) scans, and CT angiography.

For the final analysis, 37 patients were included and divided into two cohorts:

  1. Surgical Group (n=12): Patients who underwent PTE.
  2. Medical Group (n=25): Patients treated with vasodilator drugs.

During the study period, PTE was not yet available locally in the UAE. Consequently, surgical candidates were referred to international centers of excellence in the United States, United Kingdom, Austria, and France. Medical therapy involved a stepwise escalation from monotherapy—typically riociguat—to dual and triple combination therapies.

Key Findings: The "Youth Factor"

One of the most striking findings of the registry is the median age of the UAE cohort: 46 years. This is nearly two decades younger than the mean age reported in European registries, which typically hover around 68 years. This suggests a different clinical profile in the Gulf region, potentially driven by genetic predispositions, environmental risk factors, or earlier clinical presentation.

Demographically, the cohort was predominantly female (68%) and Emirati (62%).

Treatment Outcomes and Survival

The study highlights a stark contrast between surgical and medical outcomes:

  • Survival Rates: The surgical group achieved a 100% survival rate at the 1-, 3-, and 5-year marks. In contrast, the medical group saw survival rates of 86.4% at one year, dropping to 68% at three and five years.
  • Functional Improvement: The surgical group showed statistically significant improvements in WHO Functional Class (p=0.008) and NT-proBNP levels (p=0.04). Most surgical patients were able to discontinue all vasodilator medications post-operatively.
  • Risk Stratification: By the final follow-up, 75% of the surgical group met "low-risk" criteria according to the Simplified French model, compared to only 16% of the medical group.
  • Medical Escalation: The medical group required aggressive intervention, with 25% of patients escalating to triple therapy. This rate is significantly higher than the 2% reported in some European registries, indicating a more rapid disease progression or a more severe baseline state in this cohort.

Socioeconomic Barriers to Care

A critical insight from this registry is the impact of socioeconomic factors on clinical outcomes. Six patients were identified as surgical candidates but were unable to undergo PTE due to a lack of financial support or insurance coverage for international travel. This highlights a significant gap in healthcare delivery for specialized surgical needs and underscores the necessity of localizing advanced treatments.

Limitations and Future Directions

The study is limited by its retrospective nature and a relatively small sample size, which may affect the statistical power of subgroup comparisons. Additionally, because surgeries were performed at various international institutions, the results reflect a range of surgical expertise rather than a single UAE standard of care.

However, the landscape is shifting. The recent establishment of a local PTE program at Cleveland Clinic Abu Dhabi is expected to increase the number of patients receiving curative surgery. Future research will focus on the outcomes of this local program, providing a more controlled look at CTEPH management within the UAE's own healthcare infrastructure.

Conclusion

This first UAE registry confirms that CTEPH in the region affects a significantly younger population than in the West. While medical management remains a challenge with a 68% five-year survival rate, surgical intervention offers excellent outcomes. The transition toward localizing PTE surgery is a vital step in overcoming socioeconomic barriers and improving the long-term prognosis for CTEPH patients in the Gulf.

Summary updated

Abstract

Abstract Background The aim of the study was to present the first United Arab Emirates (UAE) Chronic Thromboembolic Pulmonary Hypertension registry of patients’ clinical characteristics, hemodynamic parameters, and treatment outcomes. Methods This was a retrospective study describing all adult patients who were diagnosed with Chronic Thromboembolic Pulmonary Hypertension (CTEPH) between January 2015 and April 2022 in a tertiary referral center in Abu Dhabi, United Arab Emirates (UAE). Ethics Statement IRB and Research Ethics Committee approval was obtained under REC number A-2017-030. Researchers had access to the anonymized electronic medical records with fully anonymized data for analysis of retrospective data collected from July 2015 till April 2022. IRB and REC waived the requirement for informed consent. Results A total of 39 consecutive patients were diagnosed with CTEPH during the seven years of the study. Two patients who had pulmonary artery balloon angioplasty (BPA) were not included in the analysis. Twelve out of the 37 patients (56%) had pulmonary thrombo-endarterectomy (PTE) and were designated as the surgical group, the rest were designated the medical group. The patients were followed for a median of 11 months [IQR: 6-22.5]. Most of the patients in the medical group were started on dual then subsequently escalated to triple combination therapy. Most of the patients in the surgical group stopped the vasodilator therapy. The 1-, 3- and 5-year medical group survival rates were 80%, 68% and 68%, respectively. None of the patients in the surgical group died. Conclusion This is the first registry of CTEPH patients from a single tertiary referral center in UAE. Our cohort was younger than ones reported in the Western World but similar to the one reported in Saudi Arabia. The medical group mortality is comparable to other major registries. The recent introduction of PTE program in our center is likely to increase number of surgical patients.
BibTeX
@misc{saleh2023chronic,
  author = {Khaled Saleh and Jihad Mallat and Kelly Dougherty and Mohannad Ghanem and Ahmed Ghorab and Reem Al‐Saadi and Manyoo Agrawal and Simi Salim and Sara Abdalla and Naureen Khan and Hani Sabbour},
  title = {{Chronic thromboembolic pulmonary hypertension in UAE: the first reported seven year outcomes from a tertiary center in UAE}},
  year = {2023},
  doi = {10.1101/2023.11.05.23298119},
  howpublished = {medRxiv},
}
Figure